| Yttrium-90 Carbon Microsphere Radioembolization in Previously Treated Hepatocellular Carcinoma (NCT07657273) | Second Affiliated Hospital of Guangzhou Medical University | 2026-06-22 |
| A Study to Evaluate the Safety and Pharmacokinetics of RC001 in Children With Dravet Syndrome (NCT07675746) | Second Affiliated Hospital of Guangzhou Medical University | 2025-12-22 |
| Lacosamide Intravenous Injection for Emergency Termination of Status Epilepticus (NCT06966830) | Second Affiliated Hospital of Guangzhou Medical University | 2025-06-06 |
| Herpes Simplex Virus Type 1 Infection/Reactivation of Patients With Severe Pneumonia（the HSV-SP Study） (NCT06936683) | Second Affiliated Hospital of Guangzhou Medical University | 2025-06-01 |
| Triple Hypoglycemic Regimens In Patients With Newly Diagnosed Type 2 Diabetes Mellitus (NCT07374328) | Second Affiliated Hospital of Guangzhou Medical University | 2025-06-01 |
| Lenvatinib, Sintilimab, and DEB-TACE With/Without HAIC for HCC >7 cm With PVTT (NCT06904183) | Second Affiliated Hospital of Guangzhou Medical University | 2025-04-01 |
| Lenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCC (NCT06904196) | Second Affiliated Hospital of Guangzhou Medical University | 2025-04-01 |
| Y-90 SIRT for Unresectable HCC Larger Than 7cm (NCT06707233) | Second Affiliated Hospital of Guangzhou Medical University | 2024-12-01 |
| Stem Cell Derived Exome for Treatment of Diabetic Foot (NCT06480123) | Second Affiliated Hospital of Guangzhou Medical University | 2024-08-01 |
| Lenvatinib Plus DEB-TACE and HAIC vs. Lenvatinib Plus DEB-TACE for Large HCC With PVTT (NCT06492395) | Second Affiliated Hospital of Guangzhou Medical University | 2024-08-01 |
| Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma. (NCT06492408) | Second Affiliated Hospital of Guangzhou Medical University | 2024-07-01 |
| Neoadjuvant Intra-tumor Double Immunotherapy for Lung Cancer. (NCT06492421) | Second Affiliated Hospital of Guangzhou Medical University | 2024-07-01 |
| Checkpoint Inhibitor Combinations Therapy as First Line for HCC Via IT (NCT06482801) | Second Affiliated Hospital of Guangzhou Medical University | 2024-06-10 |
| Anti-cancer DC Cell Vaccination to Treat Solid Tumors (NCT06477614) | Second Affiliated Hospital of Guangzhou Medical University | 2024-06-05 |
| Anti-cancer Neoantigen Polypeptide Vaccine to Treat Solid Tumors (NCT06195293) | Second Affiliated Hospital of Guangzhou Medical University | 2024-06-04 |
| GPC3/Mesothelin-CAR-γδT Cells Against Cancers (NCT06196294) | Second Affiliated Hospital of Guangzhou Medical University | 2024-05-10 |
| Anti-cancer Neoantigen mRNA Vaccine to Treat Solid Tumors (NCT06195384) | Second Affiliated Hospital of Guangzhou Medical University | 2024-05-08 |
| Sintilimab Plus Bevacizumab and SIRT for Intermediate-advanced HCC (NCT06397222) | Second Affiliated Hospital of Guangzhou Medical University | 2024-05-01 |
| DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC (NCT06397235) | Second Affiliated Hospital of Guangzhou Medical University | 2024-05-01 |
| Checkpoint Inhibitor Combinations Therapy as First Line for Inoperable Lung Cancer Via IT (NCT06483347) | Second Affiliated Hospital of Guangzhou Medical University | 2024-04-04 |
| Interventional Software for Multi-immunotherapy of Solid Tumors (NCT06478108) | Second Affiliated Hospital of Guangzhou Medical University | 2024-04-01 |
| Avatrombopag for HCC Patients With Thrombocytopenia Who Intend to Undergo TACE and/or HAIC (NCT06001567) | Second Affiliated Hospital of Guangzhou Medical University | 2023-08-14 |
| Lenvatinib, Sintilimab Plus SIRT for Unresectable HCC (NCT05992584) | Second Affiliated Hospital of Guangzhou Medical University | 2023-08-10 |
| SIRT for Potentially Resectable HCC (NCT05994859) | Second Affiliated Hospital of Guangzhou Medical University | 2023-08-10 |
| Tirellizumab Combined With Chemotherapy Monotherapy for Non-small Cell Lung Cancer (NCT05965102) | Second Affiliated Hospital of Guangzhou Medical University | 2023-08-01 |
| Aribulin Combined With Carboplatin and Bevacizumab in the Treatment of Ovarian Cancer (NCT05965141) | Second Affiliated Hospital of Guangzhou Medical University | 2023-08-01 |
| Sintilimab+Bevacizumab+TACE vs. Lenvatinib+TACE for Advanced HCC (NCT05985798) | Second Affiliated Hospital of Guangzhou Medical University | 2023-08-01 |
| Calizumab Combined With Bevacizumab and Capecitabine in the Treatment of Head and Neck Squamous Cell Carcinoma (NCT05965154) | Second Affiliated Hospital of Guangzhou Medical University | 2023-08-01 |
| Effect of Heart Rate Control With Ivabradine on Hemodynamic in Patients With Sepsis (NCT05882708) | Second Affiliated Hospital of Guangzhou Medical University | 2023-06-01 |
| ExtraCorporeal Membrane Oxygenation in the Therapy for REfractory Septic Shock With Cardiac Function Under Estimated (NCT05184296) | Second Affiliated Hospital of Guangzhou Medical University | 2023-05-01 |
| Mesothelin/GPC3/GUCY2C-CAR-T Cells Against Cancers (NCT05779917) | Second Affiliated Hospital of Guangzhou Medical University | 2023-03-10 |
| An Exploratory Clinical Study of Photodynamic Therapy Combined With Sonodynamic Therapy in Cholangiocarcinoma (NCT05580328) | Second Affiliated Hospital of Guangzhou Medical University | 2022-12-01 |
| Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC (NCT05608213) | Second Affiliated Hospital of Guangzhou Medical University | 2022-11-02 |
| Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC (NCT05608200) | Second Affiliated Hospital of Guangzhou Medical University | 2022-11-02 |
| Clinical Analysis of Simultaneous Pancreas-kidney Transplantation for End-stage Renal Disease Associated With Diabetes Mellitus (NCT05497232) | Second Affiliated Hospital of Guangzhou Medical University | 2022-09-01 |
| SIRT or TACE Plus Lenvatinib and PD-(L)1 Inhibitor in High Burden HCC (NCT06916546) | Second Affiliated Hospital of Guangzhou Medical University | 2022-06-01 |
| CLDN6/GPC3/Mesothelin/AXL-CAR-NK Cell Therapy for Advanced Solid Tumors (NCT05410717) | Second Affiliated Hospital of Guangzhou Medical University | 2022-06-01 |
| EGFR/B7H3 CAR-T on Lung Cancer and Triple Negative Breast Cancer (NCT05341492) | Second Affiliated Hospital of Guangzhou Medical University | 2022-05-01 |
| DEB-TACE+HAIC vs. HAIC for Large HCC (NCT05263219) | Second Affiliated Hospital of Guangzhou Medical University | 2022-02-10 |
| Donafenib Plus Sintilimab for Advanced HCC (NCT05162352) | Second Affiliated Hospital of Guangzhou Medical University | 2021-12-04 |
| Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors (NCT05187338) | Second Affiliated Hospital of Guangzhou Medical University | 2021-11-01 |
| DEB-TACE vs. cTACE as Conversion Therapy for Unresectable Large HCC (NCT04967482) | Second Affiliated Hospital of Guangzhou Medical University | 2021-07-09 |
| TACE Plus Multikinase Inhibitor and I-125 Seeds Brachytherapy for HCC With Branch PVTT (NCT04967495) | Second Affiliated Hospital of Guangzhou Medical University | 2021-07-09 |
| Intratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Release for Advanced Solid Tumors (NCT04952272) | Second Affiliated Hospital of Guangzhou Medical University | 2021-03-01 |
| Regorafenib Plus Sintilimab vs. Regorafenib as the Second-line Treatment for HCC (NCT04718909) | Second Affiliated Hospital of Guangzhou Medical University | 2021-01-09 |
| Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors (NCT04842812) | Second Affiliated Hospital of Guangzhou Medical University | 2021-01-01 |
| Enhanced Recovery After Surgery for SPK Transplantation Recipients (NCT06095544) | Second Affiliated Hospital of Guangzhou Medical University | 2021-01-01 |
| Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors (NCT04803318) | Second Affiliated Hospital of Guangzhou Medical University | 2021-01-01 |
| The Feasibility of Sugammadex for General Anesthesia in Patients Undergoing Kidney and Pancreas Transplantation Surgery (NCT04944303) | Second Affiliated Hospital of Guangzhou Medical University | 2020-12-18 |
| Intra-tumor Injection of Drug-eluting Microspheres With Multiple Drugs (NCT04770207) | Second Affiliated Hospital of Guangzhou Medical University | 2020-11-01 |
| TACE Combined With Sintilimab and Bevacizumab for Unresectable HCC (NCT04592029) | Second Affiliated Hospital of Guangzhou Medical University | 2020-10-21 |
| TACE Combined With Lenvatinib and Sintilimab for Advanced HCC (NCT04599790) | Second Affiliated Hospital of Guangzhou Medical University | 2020-10-01 |
| TACE Combined With Sorafenib and Tislelizumab for Advanced HCC (NCT04599777) | Second Affiliated Hospital of Guangzhou Medical University | 2020-10-01 |
| Preadmission Metformin Exposure and Incidence of Acute Kidney Injury (NCT04631289) | Second Affiliated Hospital of Guangzhou Medical University | 2020-08-01 |
| Study of CXCR5 Modified EGFR Targeted CAR-T Cells for Advanced NSCLC (NCT05060796) | Second Affiliated Hospital of Guangzhou Medical University | 2019-09-01 |
| CRRT Timing in Sepsis-associated AKI in ICU (NCT03175328) | Second Affiliated Hospital of Guangzhou Medical University | 2019-08-22 |
| Lenvatinib Plus DEB-TACE With/Without FOLFOX-HAIC for Large HCC With PVTT (NCT06265883) | Second Affiliated Hospital of Guangzhou Medical University | 2019-07-01 |
| Induced-T Cell Like NK Cellular Immunotherapy for Cancer Lack of MHC-I (NCT03882840) | Second Affiliated Hospital of Guangzhou Medical University | 2019-01-01 |
| IT or IA Infusion of PD1/PDL1/CTLA4 Inhibitors Versus IV for Immunotherapy of Head/Neck Cancers (HNC) (NCT03952065) | Second Affiliated Hospital of Guangzhou Medical University | 2019-01-01 |
| Infusion of PD1/PDL1/CTLA4 Inhibitors Via Hepatic Arterial for Immunotherapy of Hepatocellular Carcinoma (NCT03949231) | Second Affiliated Hospital of Guangzhou Medical University | 2019-01-01 |
| TCR-T Cell Immunotherapy of Lung Cancer and Other Solid Tumors (NCT03778814) | Second Affiliated Hospital of Guangzhou Medical University | 2018-12-01 |
| Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors (NCT03755739) | Second Affiliated Hospital of Guangzhou Medical University | 2018-11-01 |
| Evaluating the Safety and Efficacy of Pembrolizumab Combined With MWA for Advanced NSCLC (NCT03769129) | Second Affiliated Hospital of Guangzhou Medical University | 2018-11-01 |
| TACE Combined With Iodine-125 Seeds Implantation for HCC (NCT03322280) | Second Affiliated Hospital of Guangzhou Medical University | 2018-07-01 |
| Restricted Calorie Ketogenic Diet as a Treatment in Malignant Tumors (NCT03160599) | Second Affiliated Hospital of Guangzhou Medical University | 2018-03-01 |
| Pregabalin Treatment and Prevention Post-herpetic Neuralgia (NCT03186443) | Second Affiliated Hospital of Guangzhou Medical University | 2017-10-01 |
| HLA Screening in Reducing the Risk of Antiepileptic Drug-induced Cutaneous Adverse Reactions (NCT03184597) | Second Affiliated Hospital of Guangzhou Medical University | 2017-08-01 |
| GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T Cells Against Cancers (NCT03198052) | Second Affiliated Hospital of Guangzhou Medical University | 2017-07-01 |
| GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression (NCT03198546) | Second Affiliated Hospital of Guangzhou Medical University | 2017-07-01 |
| iCAGES-guided Precision Therapy for Cancers in Contrast to Standard Care or IHC-guided Theray (NCT03192501) | Second Affiliated Hospital of Guangzhou Medical University | 2017-07-01 |
| A Study of Anti-CD19 CAR-T Cell Immunotherapy for Refractory /Relapsed B Cell Malignancies (NCT03191773) | Second Affiliated Hospital of Guangzhou Medical University | 2017-06-30 |
| Efficacy and Safety of Weight-Based Insulin Titration Regimen in Hospitalized Patients With Type 2 Diabetes (NCT03220919) | Second Affiliated Hospital of Guangzhou Medical University | 2017-06-01 |
| Islet Allotransplantation for Type 1 Diabetic Patients (NCT03259256) | Second Affiliated Hospital of Guangzhou Medical University | 2017-04-23 |